HSBC Holdings
ACRS icon

HSBC Holdings’s Aclaris Therapeutics ACRS Stock Holding History

HSBC Holdings’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-46,358
Closed -$57.5K – 2912
2024
Q1 		$57.5K Buy
+46,358
New +$55.3K ﹤0.01% 2922
2023
Q4 		– Sell
-246,587
Closed -$1.67M – 2706
2023
Q3 		$1.67M Sell
246,587
-3,255
-1% -$27.8K ﹤0.01% 1528
2023
Q2 		$2.61M Buy
+249,842
New +$2.26M ﹤0.01% 1327

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

HSBC Holdings's ACRS Position: Q2 2024 in Review

HSBC Holdings sold out of Aclaris Therapeutics (ACRS) in Q2 2024, closing a stake of 46,358 shares — an estimated $57.5K sold.

HSBC Holdings first reported a position in ACRS in Q2 2023 and held it in 3 quarters. The position peaked at $2.61M in Q2 2023. 98 funds tracked by Wall St. Rank hold ACRS as of Q2 2024.

  • HSBC Holdings reported no remaining Aclaris Therapeutics position as of Q2 2024 after selling out during the quarter.
  • HSBC Holdings sold 46,358 Aclaris Therapeutics shares in Q2 2024, an estimated $57.5K.
  • HSBC Holdings first reported a position in Aclaris Therapeutics in Q2 2023 and held it in 3 quarters.
  • HSBC Holdings's Aclaris Therapeutics position peaked at $2.61M in Q2 2023.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2024.

Based on HSBC Holdings's 13F filing for Q2 2024, filed 12 Aug 2024.